ImmunityBio (NASDAQ:IBRX) Trading Up 8.1%

ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating)’s stock price was up 8.1% on Friday . The stock traded as high as $3.21 and last traded at $3.19. Approximately 49,528 shares traded hands during trading, a decline of 98% from the average daily volume of 2,091,260 shares. The stock had previously closed at $2.95.

Separately, Piper Sandler cut their target price on shares of ImmunityBio from $20.00 to $10.00 in a report on Friday, May 27th.

The firm’s fifty day moving average price is $3.92 and its two-hundred day moving average price is $5.39.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in ImmunityBio by 43.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,907 shares of the company’s stock worth $129,000 after acquiring an additional 6,896 shares in the last quarter. Advisory Services Network LLC purchased a new stake in ImmunityBio in the 1st quarter worth $636,000. Toroso Investments LLC purchased a new stake in ImmunityBio in the 1st quarter worth $63,000. Point72 Hong Kong Ltd increased its holdings in ImmunityBio by 2,136.0% in the 1st quarter. Point72 Hong Kong Ltd now owns 6,149 shares of the company’s stock worth $34,000 after acquiring an additional 5,874 shares in the last quarter. Finally, Delphia USA Inc. purchased a new stake in ImmunityBio in the 1st quarter worth $143,000. 8.67% of the stock is owned by institutional investors.

ImmunityBio Company Profile (NASDAQ:IBRX)

ImmunityBio, Inc, a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.

Further Reading